REGN Stock - Regeneron Pharmaceuticals, Inc.
Unlock GoAI Insights for REGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B |
| Gross Profit | $12.23B | $10.87B | $10.47B | $13.35B | $7.14B |
| Gross Margin | 86.1% | 82.9% | 86.0% | 83.1% | 84.0% |
| Operating Income | $3.99B | $4.35B | $5.39B | $8.95B | $3.58B |
| Net Income | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B |
| Net Margin | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% |
| EPS | $40.90 | $37.05 | $40.51 | $76.40 | $32.65 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Morgan Stanley | Downgrade | Equal Weight | $767 |
| November 24th 2025 | Truist | Resumed | Buy | $798 |
| November 24th 2025 | HSBC Securities | Initiation | Buy | $255 |
| November 13th 2025 | Scotiabank | Initiation | Sector Perform | $650 |
| August 14th 2025 | Rothschild & Co Redburn | Initiation | Buy | $890 |
| June 30th 2025 | Argus | Downgrade | Hold | - |
| May 30th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $662 |
| May 30th 2025 | Wells Fargo | Downgrade | Equal Weight | $580 |
| May 14th 2025 | Citigroup | Upgrade | Buy | $700 |
| April 22nd 2025 | Cantor Fitzgerald | Resumed | Overweight | $695 |
| February 5th 2025 | Leerink Partners | Upgrade | Outperform | $834← $762 |
| January 16th 2025 | UBS | Downgrade | Neutral | $738← $1130 |
| December 10th 2024 | BofA Securities | Resumed | Underperform | $565 |
| November 15th 2024 | Wolfe Research | Initiation | Outperform | $1150 |
| November 14th 2024 | Citigroup | Initiation | Neutral | $895 |
Earnings History & Surprises
REGNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 3, 2026 | $10.48 | — | — | — |
Q4 2025 | Oct 28, 2025 | $9.65 | $11.83 | +22.6% | ✓ BEAT |
Q3 2025 | Aug 1, 2025 | $8.43 | $12.89 | +52.9% | ✓ BEAT |
Q2 2025 | Apr 29, 2025 | $8.62 | $8.22 | -4.6% | ✗ MISS |
Q1 2025 | Feb 4, 2025 | $11.21 | $12.07 | +7.7% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $11.69 | $12.46 | +6.6% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $10.61 | $11.56 | +9.0% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $10.17 | $9.55 | -6.1% | ✗ MISS |
Q1 2024 | Feb 2, 2024 | $10.73 | $11.86 | +10.5% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $10.72 | $11.59 | +8.1% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $9.84 | $10.24 | +4.1% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $9.25 | $10.09 | +9.1% | ✓ BEAT |
Q1 2023 | Feb 3, 2023 | $10.03 | $12.56 | +25.2% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $9.48 | $11.14 | +17.5% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $8.53 | $9.77 | +14.5% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $9.74 | $8.93 | -8.3% | ✗ MISS |
Q1 2022 | Feb 4, 2022 | $18.35 | $21.32 | +16.2% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $10.10 | $14.37 | +42.3% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $17.53 | $25.80 | +47.2% | ✓ BEAT |
Latest News
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralAlvotech And Teva Reach US Settlement With Regeneron For AVT06 Proposed Biosimilar To Eylea Setting License Entry In Q4 2026
📈 PositiveMorgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $768
📈 PositiveWells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $745
📈 PositiveReported Sunday, Regeneron Reports ASH 2025 LINKER-MM4 Data: Lynozyfic Monotherapy Achieves VGPR+ ≥70% With 1.2-Month Median Time To Response
📈 PositiveCanaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1057
📈 PositiveBMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $850
📈 PositiveMorgan Stanley Downgrades Regeneron Pharmaceuticals to Equal-Weight, Maintains Price Target to $767
➖ NeutralRegeneron Pharmaceuticals And Tessera Therapeutics Collaborate For TSRA-196, Gene Writing Program For Alpha-1 Antitrypsin Deficiency, Tessera To Receive $150M, Inclusive Of A Cash Upfront And Equity Investment From Regeneron; Companies To Share Costs And Profits 50:50
📈 PositiveRegeneron And Sanofi's Dupixent Cuts Debilitating Itch And Hives For Patients Who Don't Respond To Antihistamines, EU Approves Dupixent As First New Treatment In A Decade For Severe Chronic Hives
📈 PositiveTruist Securities Assumes Regeneron Pharmaceuticals at Buy, Lowers Price Target of $798
📈 PositiveScotiabank Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $770
📈 PositiveHSBC Initiates Coverage On Regeneron Pharmaceuticals with Buy Rating, Announces Price Target of $890
📈 PositiveRegeneron Pharmaceuticals shares are trading higher after the FDA recently approved Eylea HD for macular edema following retinal vein occlusion.
📈 PositiveWells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $700
➖ NeutralTrading Halt: Halt status updated at 4:25:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralRegeneron Pharmaceuticals Gets FDA's Approval For Its EYLEA HD Injection 8 Mg To Treat Macular Edema Following Retinal Vein Occlusion
📈 PositiveTrading Halt: Halted at 4:05:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralRegeneron Announes European Commission Approval Of Libtayo For Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma Patients at High Risk Of Recurrence After Surgery And Radiation
📈 PositiveGovernor Hochul Announces Regeneron to Invest More Than $2 Billion Into Saratoga County Facility, Creating 1,000 New Jobs
📈 PositiveFrequently Asked Questions about REGN
What is REGN's current stock price?
What is the analyst price target for REGN?
What sector is Regeneron Pharmaceuticals, Inc. in?
What is REGN's market cap?
Does REGN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to REGN for comparison